Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Andrew Wang Added: 6 days ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive… View more
Author(s): Ahran D Arnold Added: 2 months ago
ESC Congress 2025 - EMORI-HCM finds that right ventricular pacing (iRVP) improves symptoms in obstructive hypertrophic cardiomyopathy (oHCM) patients.Dr Ahran Arnold (Imperial College London, UK) discusses findings from the EMORI-HCM study, exploring electro-mechanically optimised right ventricular pacing as a novel therapeutic approach for patients with oHCM.This interventional trial examined… View more
Author(s): Renate B Schnabel , Eva Gerdts , Added: 2 months ago
Cardiovascular disease in women is frequently underdiagnosed, with heart failure often overlooked due to subtle symptoms and persistent clinical bias. In this on-demand symposium, leading experts explore why cardiovascular disease is missed in women, the unique risks and presentations of female heart failure and how early detection of atrial fibrillation can improve outcomes. Chaired by Prof… View more
Author(s): Rasha Al-Lamee , Christopher Rajkumar , Nazli Okumus Added: 2 years ago
AHA 2023 — Investigators of ORBITA-2 trial, Dr Rasha Al-Lamee and Dr Christopher Rajkumar (Imperial College London, UK) talked with CardioNerds Ambassador, Dr Nazli Okumus about the randomised, placebo-controlled trial (NCT03742050) that compared the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy at 12 weeks.The ORBITA… View more
Author(s): Nir Uriel Added: 1 month ago
HFSA 25 - CCM-D was associated with successful defibrillation and symptom improvement in patients with HFrEF at 6 months in the INTEGRA-D Trial.Dr Nir Uriel (NewYork-Presbyterian, Columbia University Irving Medical Center, US) joins us to discuss findings from the Integra-D trial, evaluating a novel implantable device that provides both cardiac contractility modulation and defibrillation… View more
Author(s): Mandeep Mehra , Christian Inchaustegui Added: 2 years ago
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs. View more
Author(s): Yassir Javaid , Faizel Osman , Renate B Schnabel , et al Added: 2 months ago
This six-part interview series, recorded around ESC 2025, brings together leading experts to share strategies for earlier and more accurate detection of cardiovascular disease. The discussions highlight how atypical or subtle symptoms of stroke and heart failure can delay diagnosis, and why vigilance in routine practice is critical.The series also examines sex-specific differences in cardiac… View more
Author(s): Alexis Cutchins , Svetlana Blitshteyn , Rebecca Steinberg Added: 1 year ago
Postural Orthostatic Tachycardia Syndrome (POTS) is a heterogenous disorder that presents with positional tachycardia, amongst many other symptoms. Evidence for treatment options remains limited, and there are a multitude of associated conditions with overlapping symptoms which can make the diagnosis and management of POTS a difficult experience for providers and patients alike.This broadcast… View more
Author(s): Added: 4 months ago
New York Valves 25 - A substudy of TRISCEND II investigating the effect of transcatheter tricuspid valve replacement (TTVR) on preference-weighted health status showed significant benefits in patients who received TTVR.We are joined by Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, US) to discuss the findings from a substudy of the TRISCEND II trial, which aimed to create an… View more